Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
After finishing at $13.47 in the prior trading day, TG Therapeutics Inc (NASDAQ: TGTX) closed at $13.32, down -1.11%. In other words, the price has decreased by -$1.11 from its previous closing price. On the day, 2.88 million shares were traded. TGTX stock price reached its highest trading level at $13.85 during the session, while it also had its lowest trading level at $13.22.
Ratios:
Our goal is to gain a better understanding of TGTX by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.18 and its Current Ratio is at 5.92. In the meantime, Its Debt-to-Equity ratio is 0.69 whereas as Long-Term Debt/Eq ratio is at 0.68.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Goldman on August 02, 2023, Upgraded its rating to Neutral and sets its target price to $12 from $16 previously.
On May 20, 2022, BofA Securities started tracking the stock assigning a Underperform rating and target price of $5.BofA Securities initiated its Underperform rating on May 20, 2022, with a $5 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 13 ’24 when Lonial Sagar sold 5,000 shares for $15.94 per share. The transaction valued at 79,675 led to the insider holds 108,878 shares of the business.
Charney Laurence N sold 22,000 shares of TGTX for $351,340 on Mar 12 ’24. The Director now owns 215,229 shares after completing the transaction at $15.97 per share. On Jan 05 ’24, another insider, Charney Laurence N, who serves as the Director of the company, sold 17,500 shares for $19.03 each. As a result, the insider received 333,025 and left with 237,229 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TGTX now has a Market Capitalization of 2080051200 and an Enterprise Value of 1822136320. As of this moment, TG’s Price-to-Earnings (P/E) ratio for their current fiscal year is 944.68, and their Forward P/E ratio for the next fiscal year is 29.60. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.81 while its Price-to-Book (P/B) ratio in mrq is 12.57. Its current Enterprise Value per Revenue stands at 7.798 whereas that against EBITDA is 87.418.
Stock Price History:
The Beta on a monthly basis for TGTX is 2.33, which has changed by -0.57252884 over the last 52 weeks, in comparison to a change of 0.24191546 over the same period for the S&P500. Over the past 52 weeks, TGTX has reached a high of $35.67, while it has fallen to a 52-week low of $6.46. The 50-Day Moving Average of the stock is -11.55%, while the 200-Day Moving Average is calculated to be -1.21%.
Shares Statistics:
The stock has traded on average 3.45M shares per day over the past 3-months and 2963710 shares per day over the last 10 days, according to various share statistics. A total of 151.42M shares are outstanding, with a floating share count of 139.77M. Insiders hold about 9.56% of the company’s shares, while institutions hold 58.71% stake in the company. Shares short for TGTX as of 1713139200 were 35711438 with a Short Ratio of 10.34, compared to 1710460800 on 34185451. Therefore, it implies a Short% of Shares Outstanding of 35711438 and a Short% of Float of 28.350002000000003.
Earnings Estimates
The market rating of TG Therapeutics Inc (TGTX) is currently shaped by the ongoing analysis conducted by 7.0 analysts closely monitoring its performance.On average, analysts expect EPS of -$0.04 for the current quarter, with a high estimate of $0.05 and a low estimate of -$0.12, while EPS last year was -$0.28. The consensus estimate for the next quarter is -$0.06, with high estimates of -$0.01 and low estimates of -$0.15.
Analysts are recommending an EPS of between $0.26 and -$0.51 for the fiscal current year, implying an average EPS of -$0.09. EPS for the following year is $0.53, with 8.0 analysts recommending between $0.93 and -$0.11.
Revenue Estimates
7 analysts predict $54.58M in revenue for the current quarter. It ranges from a high estimate of $59M to a low estimate of $46M. As of the current estimate, TG Therapeutics Inc’s year-ago sales were $7.8MFor the next quarter, 7 analysts are estimating revenue of $56.89M. There is a high estimate of $59.4M for the next quarter, whereas the lowest estimate is $52.11M.
A total of 8 analysts have provided revenue estimates for TGTX’s current fiscal year. The highest revenue estimate was $342.75M, while the lowest revenue estimate was $239.76M, resulting in an average revenue estimate of $267.59M. In the same quarter a year ago, actual revenue was $233.66MBased on 8 analysts’ estimates, the company’s revenue will be $427.58M in the next fiscal year. The high estimate is $540.3M and the low estimate is $326.92M.
